Mesothelioma Hub Blog

The U.S. Environmental Protection Agency released a draft plan to hand off cleanup efforts in Libby, Montana to local government agencies.

Lung cancer kills more men and women each year in the United States than any other form of cancer. However, early detection and effective treatments are helping patients live longer and even beat the disease. Educating the Public About a Deadly Disease November is Lung Cancer Awareness Month. Each year, members of the medical community, … Continued

The combination of imaging features with a history of asbestos exposure may be enough information to diagnose pleural mesothelioma.

A new non-invasive treatment that combines chemotherapy drugs with electrical currents to shrink mesothelioma tumors appears to be working for a group of patients. Clinical Trial Results Are Positive  Researchers have released the results of a phase 2 STELLAR clinical trial testing Novocure’s TTF-100L™ “Tumor Treating Fields” (TTF) system combined with six rounds of first-line … Continued

Eating a healthy diet is important for cancer patients to maintain proper nutrition. There are 5 simple ways mesothelioma patients can improve diet.

Johnson & Johnson Initiates Voluntary Recall of Baby Powder UPDATE: Johnson & Johnson says there’s no asbestos in a batch of baby powder it voluntarily recalled on October 18. The lot, a total of 33,000 bottles, was pulled from shelves earlier this month after the Food and Drug Administration (FDA) found trace amounts of the … Continued

The European Thoracic Oncology Platform (ETOP) recently completed a disappointing phase 3 trial for mesothelioma treatment.

Phase II of a clinical trial is recruiting mesothelioma patients to test the effectiveness of two immunotherapy medications in combination.

Each year on September 26th, the medical community observes Mesothelioma Awareness Day. This year, Mesothelioma Hub remembers Inez St. John.

Making Immunotherapy Mainstream An immunotherapy procedure showing promise in the treatment of mesothelioma may soon be covered under Medicare. In August, the Centers for Medicare & Medicaid Services (CMS) approved the use of Chimeric Antigen Receptor, (CAR T-cell), therapy in patients with two specific cancers: non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia.  CAR T-cell … Continued